Oramed Pharmaceuticals Inc. (ORMP) — Financial statements
Income statement, balance sheet, and cash flow for Oramed Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2 | 0.00↓100.0% | 1↓50.4% | 3↑0.0% | 3 | |
| Cost of Revenue | 2↑929.5% | 0.19 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.01↑106.7% | -0.19↓114.4% | 1↓50.4% | 3↑0.0% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 6↑0.9% | 6↓29.5% | 9↓67.5% | 28↑31.7% | 21 | |
| General & Administrative Expenses | 9↑35.0% | 6↓23.4% | 8↓39.0% | 14↑132.6% | 6 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.29↓115.5% | 2 | 0.00 | |
| SG&A Expenses | 9↑35.0% | 6↓20.7% | 8↓48.0% | 16↑163.8% | 6 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 15↑18.2% | 13↓25.3% | 17↓60.5% | 43↑60.8% | 27 | |
| Total Costs & Expenses | 17↑33.7% | 13↓25.3% | 17↓60.5% | 43↑60.8% | 27 | |
| Operating Results | ||||||
| Operating Income | -15↓18.1% | -13↑18.9% | -16↑61.2% | -41↓67.6% | -24 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.19↓1.5% | 0.20↓94.6% | 4↑4603.9% | 0.08 | |
| EBITDA | -15↓1.4% | -15↓303.2% | 7↑119.8% | -37↓47.7% | -25 | |
| EBIT | 0.00↑100.0% | -15↓311.5% | 7↑117.6% | -41 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↑100.0% | -0.85↓119.2% | 4↑24.4% | 4↑947.8% | 0.34 | |
| Interest Income | 0.00 | 0.00↓100.0% | 8↑124.6% | 4↑929.7% | 0.35 | |
| Interest Expense | 0.00↓100.0% | 0.85↓76.2% | 4 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00↓100.0% | 2↑110.0% | -23 | 0.00 | 0.00 | |
| Other Income / Expenses | 90↑2980.3% | -3↓115.1% | 21↑610.9% | 3↑228.6% | 0.89 | |
| Income Before Tax | 75↑573.1% | -16↓412.9% | 5↑113.5% | -38↓63.8% | -23 | |
| Income Tax Expense | 0.00↓100.0% | 3 | 0.00↓100.0% | 0.10↑103.5% | -3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 75↑494.3% | -19↓475.5% | 5↑113.5% | -38 | — | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 75↑494.3% | -19↓445.8% | 6↑114.6% | -38↓69.8% | -22 | |
| Bottom-Line Net Income | 75↑495.2% | -19↓445.0% | 6↑114.6% | -38↓69.8% | -22 | |
| EPS (Basic) | 1.53↑425.5% | -0.47↓435.7% | 0.14↑114.4% | -0.97↓24.4% | -0.78 | |
| EPS (Diluted) | 1.50↑419.1% | -0.47↓435.7% | 0.14↑114.4% | -0.97↓24.4% | -0.78 | |
| Weighted Average Shares | 41↑1.4% | 41↑1.3% | 40↑3.4% | 39↑37.0% | 28 | |
| Weighted Average Diluted Shares | 42↑3.9% | 41↑0.6% | 41↑4.0% | 39↑37.0% | 28 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.